论文部分内容阅读
研究了成纤维细胞介导的ＩＬ－３基因疗法、ＩＬ－６基因疗法以及两者联合后对造血系统的影响。结果发现，单用ＩＬ－３基因疗法的小鼠白细胞总数、中性粒细胞、骨髓ＣＦＵ－ＧＭ、ＣＦＵ－ＭＫ等显著上升，但血小板上升程度软弱；单用ＩＬ－６基因疗法的小鼠血小板、中性粒细胞、骨髓ＣＦＵ－ＧＭ、ＣＦＵ－ＭＫ等显著上升，但白细胞总数上升不明显；当两者联合后可使血小板、中性粒细胞、骨髓ＣＦＵ－ＧＭ、ＣＦＵ－ＭＫ上升更为显著；且达高峰时间提前。表明联合应用成纤维细胞介导的ＩＬ－３基因疗法和ＩＬ－６基因疗法能比单一疗法更显著增强机体骨髓造血功能，使外周血细胞升高，从而为肿瘤患者放化疗后机体造血功能低下的治疗开辟了新的途径。
The effects of fibroblast-mediated IL-3 gene therapy, IL-6 gene therapy and their combination on hematopoietic system were studied. As a result, it was found that the total number of white blood cells, neutrophils, bone marrow CFU-GM, CFU-MK, etc. of mice treated with IL-3 gene alone increased significantly, but platelet rise was weak; platelets of IL-6 gene therapy alone were used in mice. The number of neutrophils, bone marrow CFU-GM, CFU-MK, etc. increased significantly, but the total number of leukocytes did not increase significantly; when the two combined, platelet, neutrophils, bone marrow CFU-GM, CFU-MK rose more Significant; and ahead of peak time. It was shown that the combined use of fibroblast-mediated IL-3 gene therapy and IL-6 gene therapy can significantly enhance the hematopoietic function of the bone marrow and increase the peripheral blood cells in comparison with monotherapy. This results in hypoplastic hematopoiesis after radiotherapy and chemotherapy in tumor patients. Treatment opens up new avenues.